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Recognition of a B Cell Leukemia-Associated Minor 
Histocompatibility Antigen by CTL1
Harry Dolstra,2* Hanny Fredrix,* Frank Preijers,* Els Goulmy,* Carl G. Figdor,
Theo M. de Witte,* and Elly van de Wiel-van Kemenade*
CTL directed against minor histocompatibility Ags (mHag) play a major role in antileukemia reactivity after HLA-identica! bone 
marrow transplantation. Some of these mHag are restricted to hemopoietic cells, others show a broad tissue expression. 
Therefore, antileukemia reactivity is often associated with graft-vs-host disease. Here, we report the identification of a B cell 
leukemia-associated mHag, HB-1, recognized by a CDS* CTL clone derived from peripheral blood of an acute lymphoblastic 
B cell leukemia patient who has been treated by HLA-matched bone marrow transplantation. Interestingly, the CTL clone that 
recognizes HB-1 exhibits specific cytotoxicity toward leukemic as well as EBV-transformed B cells, but not against untrans­
formed B cells. Moreover, the CTL clone does not lyse PHA-stimulated T cell blasts, monocytes, and fibroblasts, indicating that 
HB-1 is mainly expressed by transformed B cells. Further analysis reveals that HB-1 is restricted by HLA-B44 (both B*44Q2 and 
B*4403) and that 28% of HLA-B44-positive individuals express HB-1. These findings demonstrate that leukemia-associated 
mHag with a restricted tissue distribution, such as HB-1, elicit CTL reactivity in vivo* These Ags are of potential use in immu­
notherapy against leukemia because they generate antileukemia reactivity that is not associated with graft-vs-host disease. The
fournal of Immunology, 1997, 158: 560-565 .
T cell reactivity induced by disparities in minor histocom­patibility Ags (mHag)3 between donor and patient plays a major role in HLA-identical bone manow transplantation (BMT) (1-3). CTL directed against mHag of the patient generally 
cause graft-vs-host disease (GVHD), which, although a complica­
tion in allogeneic BMT, is strongly associated with graft-vs-leu­
kemia (GVL) reactivity (4, 5). Depletion of the allogeneic bone 
marrow graft from T cells to reduce occurrence of GVHD is cor­
related with an increased risk of recurrent leukemia (5). GVL re­
activity is not observed in transplantation between identical twins 
in which anti-mHag responses are lacking (5). These clinical data 
indicate that CTL responses against mHag may be responsible for 
the GVL reactivity.
mHag are derived from intracellular proteins, and CTL that rec­
ognize these mHag in a MHC-restricted manner have been isolated 
from BMT recipients (6-9). Expression of some mHag is re­
stricted to hemopoietic cells, including leukemic cells; others are 
expressed by cells of all tissues (8, 10-14). The identity of mHag, 
besides the recently identified HA-2 and H-Y antigenic peptides
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(15, 16), is unknown. HA-2 is most probably derived from an as 
yet unidentified nomfilament-forming class I myosin protein and 
H-Y from the male-specific SMCY protein (15, 16).
Since mHag expressed by all host tissues induce GVHD and 
GVL, it is of great importance to identify leukemic restricted Ags 
because these exert antileukemia reactivity without GVHD. Clin­
ical data and in vitro studies support the notion that GVL may 
indeed exist without the development of GVHD (4, 5, 13, 17, 18). 
Here, we investigated whether leukemia cell restricted mHag-spe­
cific CTL can be isolated from patients after HLA-identical BMT. 
We have identified a mHag-speciiic CTL clone directed against a 
new mHag, designated HB-1. HB-1 is mainly expressed by B- 
acute lymphoblastic leukemia (B-ALL) cells and by EBV-trans­
formed B cells, and is recognized in association with HLA-B44.
Materials and Methods
mAh and immunofluorescence analysis
The following mAb were used for immunofluorescence analysis or for 
inhibition of cytotoxicity: TS2/18 (CD2), SPV-T3b (CD3), RIV-7 (CD4), 
WT82 (CDS), LI5 (CD 11a), F10.2 (CD54), TS2/9 (CD58), CRI304.3 
(anti-TCRBV6S1), OT145 (anti-TCRBV6S7), E17.5F3 (anti-TCRBV17), 
W6/32 (anti-HLA-class I), and Q5/13 (anti-HLA-DR/DP). Immunofluo­
rescence was performed by the indirect method. FITC-conjugated goat 
F(ab#)2 anti-mouse IgG and IgM (Tago Immunologies, Camarillo, CA) was 
used for staining followed by analysis by an Epics XL flow cytometer 
(Coulter Electronics, Hialeah, FL).
CTL cultures
CD8+'T cells were isolated from PBL of patient MP (a 42-yr-old woman 
with a B-ALL) 9 mo after an HLA-identical BMT using anti-CD8 immu- 
nomagnetic beads (Dynal, Olso, Norway). A CTL line was established by 
stimulating CD8+ T cells (5 X  105/ml) with irradiated leukemic cells (106/ 
ml) and autologous donor PBMC as feeder cells (2.5 X 105/ml) in IMDM 
(Life Technologies, Paisley, Scotland) plus 10% human serum. On day 7, 
cells were restimulated with irradiated leukemic cells from the patient (106/ 
ml), and 100 U/ml IL-2 (Glaxo, Geneva, Switzerland) was added. From 
day 14 on, cultures were expanded and restimulated weekly with irradiated 
EB V trans formed-lymphoblastoid cell lines (EBV-LCL) of the patient pre- 
BMT (106/ml), 100 U/ml IL-2, and 5 ng/ml IL-12 (Hoffmann-La Roche, 
Nutley, NJ).
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Target cells
Leukemic cells were collected from B-ALL patients at diagnosis. Fibro­
blast cell cultures were generated from bone marrow obtained from patient 
MP pre-BMT. Fibroblasts and EBV-LCL were cultured in IMDM plus 
10% FCS. Monocytes were isolated after adherence to plastic. T cell blasts 
were generated by stimulating PBMC with 4 /xg/ml PH A in IMDM plus 
10% human serum for three days. T cell blasts were washed and further 
cultured with 100 U/ml IL-2 for three days. B cells were obtained by 
positive selection using anti-CD19 immunomagnetic beads (Dynal). B cell 
blasts were generated by stimulating 106 C D l^  B cells with 5 X 104 
CD32-transfected mouse fibroblastic L cells and 0.5 /xg/ml CD40 mAb for 
2 to 4 days. To increase susceptibility of B-ALL cells, fibroblasts, and 
CD40-sdmulated B cells to specific CTL lysis, these cells were incubated 
with 10 ng/ml TNF-a (Boehringer Ingelheim, Alkmaar, The Netherlands) 
for 2 days.
Chromium release assay
Chromium release assays were performed as previously described (19). 
Fibroblast targets were labeled with 150 fiCi 51Cr for 18 h (20).
IFN-y release assay
EBV-LCL and B cell blasts were tested for their ability to stimulate the 
production of IFN-y by the CTL. Briefly, 1G4 CTL were cultured with 3 X 
104 target cells in 200 /xl IMDM plus 10% FCS and 25 U/ml IL-2. After 
24 h, supernatant was collected and its IFN-7 content was determined by 
ELISA (CLB, Amsterdam, The Netherlands).
HLA-B44 subtyping
PCR cell lysates from 106 cells were prepared as described (21). HLA-B44 
exon 3 DNA was amplified by PCR using 50 pmol B44EX3F primer 
(5' -TCCTCCGCGGGTATG ACC AGG-3'), 50 pmol B44EX3R primer
(5'-AGCGACTCCACGCACAGGCC-3'), 0.5 mM dNTPs and 2.5 U Taq
polymerase (Life Technologies, Gaithersburg, MD) as previously de­
scribed (22). PCR products were digested with Pvull to discriminate be­
tween HLA-BH402 and -B*4403.
Cloning and sequencing of TCRB gene rearrangement
Total RNA from 106 cells was extracted using the RNAzol method (Cinna/ 
Biotecx Laboratories, Friendswood, TX) and reverse transcribed using an 
oligo(dT) primer and reverse transcriptase (Life Technologies, Gaithers­
burg, MD). TCRB cDNA was amplified by PCR using 250 pmol Cj8-N2 
primer (5'-CACAGCGACCTCGGGTGGG-3')> 250 pmol V/3-37 primer 
(5'-CGGATCCT(GT)T(AT)(CT)TGGTA(TC)C(GA)(TA)CA-3'), 0.5 mM 
dNTPs and 2.5 U Taq polymerase as previously described (23). The PCR 
product was cloned into pCRII vector by using die TA cloning kit (Invitrogen, 
San Diego, CA). Transformants were sequenced by the dideoxynucleotide 
chain termination method, and sequencing products were resolved on 
polyacrylamide gels.
Table i. TCRB expression o f  CTL culture MP1a
Results
Isolation of antileukemic CD8+ CTL
To identify mHag expressed by leukemia cells, we isolated and 
expanded CTL from patient MP by stimulating CD8+ T cells, 
obtained after HLA-identical BMT, with irradiated B-ALL cells 
and used autologous donor PBMC as feeder cells. This CTL cul­
ture showed specific cytotoxicity against EBV-LCL of patient or­
igin (51% specific lysis; E:T ratio 10:1), whereas EBV-LCL of the 
HLA-identical donor were not lysed. The CTL were of donor or­
igin and expressed TCRajB and CD8. Interestingly, TCR repertoire 
analysis of this CTL culture showed that 21 of 23 cloned TCRB 
cDNA exhibited an unique BV6S1-DEAPEG-JB2S1 rearrange­
ment (Table I). Eighty percent of the cells expressed TCRBV6S1 
analyzed by flow cytometry (Table I).
Next, TCRBV6S1-expressing cells were sorted by flow cytom­
etry. This CTL clone, MP1, efficiently lysed EBV-LCL of patient 
MP, whereas EBV-LCL of the HLA-identical donor BP were not 
killed (Fig. L4). Lysis of K562 cells was not observed. Further­
more, we observed that B-ALL cells of patient MP preincubated 
with TNF-a were lysed, whereas untreated B-ALL cells were not
No. Clones TCRBV Usage Positive Cells (%)6
21/23 6S1 80
1/23 6S7 2
1/23 17 4
aTCRB repertoire was analyzed by cloning and sequencing of rearranged 
TCRB cDNAs after PCR amplification/ as described in Materials and Methods, 
b Frequency of each detected TCRBV was analyzed by flow cytometry.
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FIGURE 1. Specific cytotoxicity of CTL clone MP1. A, Cytotoxicity 
against K562 and EBV-LCL of patient MP and donor BP. B, Cytotoxicity 
against B-ALL cells of patient MP, B-ALL cells were untreated or 
treated with 100 U/ml TNF-a for 2 days. C, Inhibition of cytotoxicity 
against TNF-a-treated B-ALL cells. Blocking studies were performed 
using purified mAb (10 ixg/ml), which was present during the assay. 
The E:T cell ratio was 1 :L  One representative experiment of three is 
shown.
killed (Fig. 15). Lysis of B-ALL cells was efficiently inhibited by 
CD3, CD8, and HLA-class I mAb, whereas mAb directed against 
CD4 and HLA-class II were ineffective (Fig. 1C). These results
1
demonstrate that CTL clone MP 1 is directed against an HLA-class 
I-restricted mHag, designated HB~1.
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Table II. Specific lysis by HB-1-specific CTL clone MP1 of a panel of EBV-LCL from relatives, unrelated sibling pairs, and unrelated 
individuals sharing one or more HLA class / Ags with patient MP
EBV-LCL Relation to Recipient HLA Type B*44 Subtype
(%) Specific Lysis* 
3:1 1:1
Relatives
MP A2 A33 B44 B60 03 63 52
BP Donor A2 A3 3 B44 B60 03 < <
PP Father A3 A33 B 7 B44 03 34 23
PC Mother A2 A26 B56 B60 < <
RP Sister A26 A33 B44 B56 03 47 33
CP Sister A26 A33 B44 B56 03 33 30
EP Sister A2 A3 B7 B60 « < <
P Brother A2 A33 B44 B60 03 < <
Unrelated sibling pairs
ROI A2 A33 B58 B62 < <
R02 A2 A3 3 B58 B62 < <
LAI A2 A33 B 7 B58 < <
LA2 A2 A3 3 B7 B58 « < <
HS1 A2 A24 B37 B44 02 < <
HS2 A2 A24 B37 B44 02 < <
VH1 A2 A23 B18 B44 03 36 34
VH 2 A2 A23 B18 B44 03 < <
VN1 A1 A2 B7 B44 02 < <
VN.2 A1 A2 B7 B44 02 < <
GET A2 A11 B8 B44 02 < <
CE2 A2 A11 B8 B44 02 < <
Unrelated individuals
KG A2 A31 B44 B6Q 02 25 23
HM A1 A3 B7 B44 03 < <
O D A11 A24 B35 B44 02 < <
OO A2 A3 B35 B44 02 < <
BR A2 B44 B60. 02 20 15
ZM A2 B44 B60 02 < <
WC A2 A29 B44 B49 03 31 22
G Y A2 A3 B18 B44 02 < <
RB A2 A11 B44 B51 02 < <
BA A2 B44 02 < <
a <  indicates <10% specific lysis.
Identification of the restriction element of H B -1
To determine the HLA molecule that presents HB-1 to CTL clone 
MP1, we tested EBV-LCL of relatives of patient MP. The results 
in Table II demonstrate that CTL clone MP1 recognizes HB-1 on 
EBV-LCL of three family members sharing expression of HLA- 
A33 and -B44 with the patient. Like EBV-LCL of the donor, EBV- 
LCL of one other HLA-A33, B44-positive family member does 
not express HB-1. These results demonstrate that HB-1 is recog­
nized in association with HLA-A33 or -B44., To further define the 
HLA restriction molecule» we tested EBV-LCL of six sibling pairs 
unrelated to patient MP expressing HLA-A3 3 or -B44. EBV-LCL 
of one of these individuals, sharing only HLA-B44 with patient 
MP, were lysed by CTL clone M P1, thus demonstrating that HB-1 
is presented by HLA-B44 (Table II). The observation that EBV- 
LCL of three out of ten randomly selected unrelated HLA-B44- 
positive individuals were also lysed confirms these data (Table II).
Expression of HB-1 by B-ALL cells
Since the HB-1-specific CTL clone MP1 was expanded by stim­
ulation with B-ALL cells, we tested B-ALL cells of randomly 
selected HLA-B44-positive patients for recognition by CTL clone 
MP1. Leukemia cells of two out of eight B-ALL patients were 
HB-1 positive (Fig. 2). B-ALL cells of patient VR were only lysed 
after preincubation with TNF-a, like B-ALL cells of patient MP. 
Interestingly; B-ALL cells of patient SC were recognized by HB- 
1-specific CTL without TNF-o: pretreatment (Fig. 2). To determine
whether B-ALL cells in general show low susceptibility to CTL- 
mediated lysis and whether this can be enhanced by TNF-a, we 
tested these cells for lysis by an anti-HLA-A2 CTL. TNF-a pre­
incubation of B-ALL cells o f  patient MP and VR increased sig­
nificantly the susceptibility to lysis by the HLA-A2 allospecific 
CTL line 1E2 (Fig. 2). In an attempt to explain the enhanced sus­
ceptibility of B-ALL cells to HB-1 specific and anti-HLA~A2 CTL 
lysis upon TNF-a treatment, we analyzed expression of MHC 
class I and adhesion molecules LFA-1, LFA-3, and ICAM-1 of 
B-ALL cells incubated with and without TNF-a. TNF-a clearly 
enhanced expression of ICAM-1 and LFA-3 of B-ALL cells (Ta­
ble III). Lysis of B-ALL cells incubated with TNF-a was com­
pletely inhibited by a combination of anti-LFA-3 and anti-ICAM-1 
mAb (Table IV). These data demonstrate that HB-1 is expressed 
by these B-ALL cells, but that significant expression of adhesion 
molecules is a prerequisite for lysis of B-ALL cells by CTL 
clone MP1.
Tissue specificity of H B-1
To determine whether HB-1 is expressed by all host cells or shows 
a restricted tissue expression, we tested lysis of fibroblasts and 
normal hemopoietic cells of patient MP, and three other HLA-B44, 
HB-1-positive individuals. Interestingly, PHA-stimulated T cell 
blasts, monocytes, and TNF-a treated fibroblasts were not lysed by 
CTL clone MP1, indicating that HB-1 is restricted to the B cell 
lineage (Fig. 3A). All cell types were efficiently killed by the
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Target cells anti HB-1
FIGURE 2. Specific cytotoxicity of CTL 
clone MP1 against B-ALL cells of three pa­
tients. HLA-B44 subtype of patient MP is 
B4403 and of patients VR and SC is B4402,. 
B-ALL cells were untreated or treated with
100 U/ml TNF-a for 2 days. The E:T cell ratio 
was 1:1*
EBV-LCL MP 
B-ALL MP 
B-ALL MP + TNF-cc
EBV-LCL VR 
B-ALL VR 
B-ALL VR + TNF-a
EBV-LCL SC 
B-ALL SC 
B-ALL SC + TNF-a
anti HLA-A2
Specific lysis (%) Specific lysis (%)
Table III, Effect of TNF-a on expression of MHC class I and 
adhesion molecuies on B-ALL cells
Relative Fluorescence Intensity
B-ALL MP B-ALL VR B-ALL SC
-TNF-a -f TNF-a ■~TNF-a +TNF-a -TNF- <x +TNF-a
Control 2 2 2 2 3 3
MHC class 1 569 568 373 436 513 616
LFA-1 11 11 36 50 16 17
LFA-3 29 36 45 102 100 123
ICAM-1 3 46 3 11 66 92
Table IV. Inhibition of cytotoxicity of CTL clone MP1 against 
TNF-a-treated B-ALL ceils
(%) Specific Lysis3
mAbfa B-ALL MP B-ALL VR B-ALL SC
Medium 26 59 35
LFA-3 + ICAM-1 5 8 9
a E:T cell ratio — 3:1,
b Blocking studies were performed using purified mAb (10 /ig/ml), which was 
present during the assay.
HLA-A2 allospecific CTL line 1E2, indicating that all target cells 
were susceptible to CTL-mediated lysis (Fig. 3A). To investigate 
B cell-specific expression of HB-1 in more detail, we tested this 
expression of in vitro TNF-a and CD40-stimulated B cell blasts of 
three HLA-B 44, HB-1-positive individuals. TNF-a/CD40-stimu­
late d B cell blasts were unable to induce IFN-7 release of CTL 
clone M P1, whereas EBV-LCL of these individuals induced a sig­
nificant release of IFN-y (Fig. 3£). These results show that HB-1 
is expressed by leukemic and EB V-transformed B cells, but not by 
activated B cells.
Discussion
In the present report, we demonstrate that CD8+ CTL specific for 
leukemia-associated mHag are present within the T cell repertoire 
o f  a leukemia patient treated by HLA-matched BMT. We identi­
fied a first example of a human B cell lineage-specific mHag, des­
ignated HB-1. Of the mHag identified so far in humans, some are 
expressed  by all tissues, others are exclusively expressed by he­
m opoietic  cells (8,10,11). We found that HB-1-specific CTL were 
not reactive against PH A-stimulated T cell blasts, monocytes, and 
fibroblasts, but showed cytolytic reactivity against leukemic and 
EB V-transformed B cells. These data show restricted expression of 
HB-1 to cells of the B cell lineage. Previously, a B cell-specific 
m H ag  has been identified in mice (24). This Ag is exclusively 
expressed by mature B cells and B cell tumors. In contrast, HB-1 
is not expressed by mature untransformed CD40-stimulated B 
cells. Therefore, HB-1 is clearly a B cell leukemia-associated Ag. 
Our results suggest that expression of HB-1 is induced by activation 
o f  a silent B cell gene in EBV and leukemia-transformed B cells. 
Further analysis of HB-1 awaits cloning of the encoding cDNA.
HB-1 is recognized in association with HLA-B44, which is a 
common HLA-B allele expressed by 23% of the Caucasian pop­
ulation (25). Among randomly selected HLA-B 44-positive indi­
viduals we found that HB-1 is expressed by 3 of 10 EBV-LCL and 
by 2 of 8 B-ALL, resulting in a phenotype frequency of 28% 
(5/18). Since amino acid substitutions among HLA subtypes can 
affect the presentation of peptides to specific T cells, it is possible 
that subtype differences bias the phenotype frequency of HB-1. 
Five subtypes of HLA-B44 have been found, but the most fre­
quently expressed subtypes are HLA-B*4402 and -B*4403 (26, 
27). HLA-B*4402 differs from HLA~B*4403 by a single amino 
acid substitution from Asp (*4402) to Leu (*4403) in position 156 
of the a 2 domain (28). Both HLA-B*4402 and -B*4403 were able 
to present HB-1 to CTL clone MP1 (Table II and Fig. 2). This is 
consistent with the finding that the peptide-binding motif of both 
subtypes is identical (29).
B-ALL cells of two out of three HLA-B44, HB-1-positive pa­
tients were only lysed by CTL clone MP1 after preincubation with 
TNF-a. This finding is in accordance with reports that lymphatic 
leukemia cells are less susceptible to lysis by CTL in vitro than 
myeloid leukemia cells and normal hemopoietic cells (14). We 
investigated whether the absence of several adhesion molecules by 
B-ALL cells might be the cause of low susceptibility to CTL lysis. 
We found that resistance to lysis correlated with low expression of 
ICAM-1 and LFA-3 by B-ALL cells. Susceptibility to CTL-me­
diated lysis of B-ALL cells was increased after incubation with 
TNF-a, which was clearly associated by an increase of ICAM-1
and LFA-3 expression.
Leukemic relapse after allogeneic BMT is a serious problem. 
Infusion of mHag-reactive donor T cells will always result in 
broad reactivity, inducing severe GVHD. Since HB-1 is expressed 
by B cells after malignant or EBV transformation, it may be an 
excellent Ag to develop immunotherapeutic protocols to eradicate
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FIGURE 3. Tissue-specific expression of HB-1. A, Cytotoxicity against EBV-LCL, PHA-stimulated T cell blasts, monocytes, and fibroblasts of 
HLA-B44, HB-1-positive individuals. The E:T cell ratio was 1:1. S, Production of IFN-y by CTL clone MP1 stimulated with CD40 activated B cell 
blasts and EBV-LCL of HLA-B44, HB-1-positive individuals. B cells were stimulated with CD40 and 100 U/ml TNF-a for 2 days. One representative 
experiment of two is shown.
residual B cell leukemia cells in BMT patients without the devel­
opment of severe GVHD. The low ICAM-1 and LFA-3 expression 
by some B-ALL cells raises the issue of tumor escape to HB-1 
specific CTL. However, serum levels of the inflammatory cyto­
kines TNF-a and IFN-y are increased in BMT recipients during 
GVH reactions and viral infections (30, 31). TNF-a and IFN-y can 
induce or up-regulate expression of MHC and adhesion molecules 
on residual leukemia cells in BMT recipients, In our view, it is 
therefore likely that B-ALL cells in BMT recipients will be sus­
ceptible to mHag-specific CTL.
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